OSOle Helmer Sjo

Ole Helmer Sjo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ole Helmer Sjo has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prognostic Impact of Lymph Node Harvest and Lymph Node Ratio in Patients With Colon Cancer

    by Ole H. Sjo, Marianne A. Merok, Aud Svindland, Arild Nesbakken

    The prognostic impact of the number of lymph nodes and ratio in colon cancer is still debated. The aim of this study was to evaluate lymph node harvest in patients with colon cancer over time, and to test the hypotheses that investigation of more lymph nodes, and low lymph node ratio in stage III patients, has positive prognostic impact. This is a prospective, observational study. This study was conducted in a single institution treating all patients with colon cancer in a defined catchment area. All patients admitted in the period 1993 to 2009 (n = 1481) were included. The primary outcomes measured were the number of examined regional lymph nodes according to treatment period, 5-year overall survival and time to recurrence, and univariate (Kaplan-Meier) and multivariate (Cox regression) analyses of prognostic factors. Nine hundred fifty (65%) patients underwent curative resection. Median number of examined lymph nodes increased from 7 to 15 (p < 0.001), and the proportion of patients with stage III disease increased from 25% to 33% (p = 0.02) during the study period. In patients with stage I to III disease, time to recurrence (proportion of patients without recurrence or death of colon cancer) improved from 65% to 82% during the period (p < 0.001). An association between lymph node count (<8 compared with ≥ 12) and overall survival was found for patients with stage II disease (57% vs 71%, p = 0.004). Hazard ratio for death within 5 years was 0.7 (p = 0.043) when 8 to 11 nodes were examined and 0.6 (p = 0.001) when ≥ 12 nodes were examined (<8 reference). In patients with stage III disease, increasing lymph node ratio was associated with reduced overall survival and time to recurrence in uni- and multivariate analyses. This study was limited by the small number of patients in each stage. The number of examined lymph nodes increased in the study period. A stage migration was observed, and time to recurrence improved in patients with stage I to III disease. In patients with stage III disease, lymph node ratio was a stronger prognostic factor than the total number of lymph nodes examined.


  • Peritoneal carcinomatosis of colon cancer origin: Highest incidence in women and in patients with right‐sided tumors

    by Ole Helmer Sjo, Marianne Berg, Marianne Arstad Merok, Matthias Kolberg, Aud Svindland, Ragnhild A. Lothe, Arild Nesbakken

    Background and Objectives: : The aim of the study was to evaluate the incidence of peritoneal carcinomatosis (PC) in a prospectively recorded series of colon cancer patients from a defined cohort and to compare clinicopathological characteristics, survival, and TP53 mutation status in primary tumors from patients with and without PC.Methods: : Clinical data from all colon cancer patients admitted in 1993–2006 were registered prospectively (n = 1,124). In a subset of PC patients, DNA was retrieved from tumor tissue and TP53 mutations analyzed and compared to the mutation status in a historical series.Results: : In the prospective series 10% of female and 7% of male patients had PC (P = 0.05). The PC patients were younger than those without PC (median 4 years, P = 0.002). The incidence of PC was 10.3% and 6.2% (P = 0.03) in patients with primary tumors in the right and left colon, respectively. TP53 was mutated in 57% of the PC patients as compared to 41% in the series of patients without PC (P = 0.05).Conclusions: : The incidence of PC was higher in right‐sided colon cancer and among women. PC patients were younger than non‐PC patients, and PC was independently associated with TP53 mutation in the primary tumor. J. Surg. Oncol.